Page last updated: 2024-11-03

procaine and Injury, Myocardial Reperfusion

procaine has been researched along with Injury, Myocardial Reperfusion in 30 studies

Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.

Research Excerpts

ExcerptRelevanceReference
"The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368."7.91Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019)
"The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368."3.91Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019)
" The purpose of this study was to evaluate clinical efficacy of the TWBC in combination with B-HTK for myocardial protection."2.69[Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection]. ( Endoh, M; Hachida, M; Ishitoya, H; Kitamura, M; Koyanagi, H; Morishita, A, 1999)
"After selective cardiac arrest with Bretschneider, captopril-treated hearts showed improved hemodynamics compared to control and the other treatment groups."1.40Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution. ( Dhein, S; Hoyer, A; Kempfert, J; Mohr, FW; Pritzwald-Stegmann, P, 2014)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.33)18.7374
1990's9 (30.00)18.2507
2000's5 (16.67)29.6817
2010's15 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, D1
Zhang, X1
Qu, D1
Han, J1
Meng, F1
Xu, M1
Zheng, Q1
Schaefer, M1
Gebhard, MM2
Gross, W1
Li, WC1
Gao, H1
Gao, J1
Wang, ZJ1
Qiang, Z1
Yu, W1
Yu, Y1
Sung, SY1
Lin, CY1
Song, JY1
Tsai, YT1
Kao, CH1
Lee, CY1
Lin, YC1
Hsu, PS1
Tsai, CS1
Hoyer, A2
Kempfert, J2
Pritzwald-Stegmann, P2
Mohr, FW2
Dhein, S2
Chen, Y1
Liu, J1
Li, S1
Yan, F1
Xue, Q1
Wang, H1
Sun, P1
Long, C1
Aarsaether, E1
Stenberg, TA1
Jakobsen, Ø1
Busund, R1
Koch, A1
Loganathan, S1
Radovits, T1
Sack, FU1
Karck, M1
Szabó, GB1
Lee, S1
Huang, CS1
Kawamura, T1
Shigemura, N1
Stolz, DB1
Billiar, TR1
Luketich, JD1
Nakao, A1
Toyoda, Y1
Wei, L2
Wu, RB2
Yang, CM2
Zheng, SY2
Yu, XY2
Viana, FF1
Shi, WY1
Hayward, PA1
Larobina, ME1
Liskaser, F1
Matalanis, G1
Lima, ML1
Fiorelli, AI1
Vassallo, DV1
Batista, PR1
Simoes, FV1
Fiorim, J1
Stefanon, I1
Pinheiro, BB1
Stolf, NA1
Gomes, OM1
Trescher, K1
Hasun, M1
Baumgartner, A1
Dietl, W1
Wolfsberger, M1
Hallström, S1
Podesser, BK1
Fuchs, F1
Messmer, K1
Kuppe, H1
Habazettl, H1
Ebel, D1
Preckel, B3
You, A1
Müllenheim, J1
Schlack, W3
Thämer, V3
Möllhoff, T1
Sukehiro, S1
Borgers, M1
Vandeplassche, G1
Van Belle, H1
Van Aken, H1
Flameng, W1
Chong, YS1
Cottier, DS1
Gavin, JB1
Hachida, M2
Ookado, A1
Nonoyama, M1
Koyanagi, H2
Mustonen, PK1
Hippeläinen, MJ1
Pöyhönen, MJ1
Rehnberg, LS1
Sakata, J1
Morishita, K1
Ito, T1
Koshino, T1
Kazui, T1
Abe, T1
Morishita, A1
Kitamura, M1
Ishitoya, H1
Endoh, M1
Keeling, IM1
Obermayr, RP1
Schneider, B1
Spieckermann, PG1
Schmiedl, A2
Richter, J2
Schnabel, PA2
Bach, F1
Bartels, U1
Ramsauer, B1
Bretschneider, HJ1
Tutterová, M1
Vavrínková, H1
Janata, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095]Phase 2110 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All Cause Mortality

Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution20
Cold Blood Cardioplegia24

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution6.0
Cold Blood Cardioplegia7.8

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution1.9
Cold Blood Cardioplegia2.6

Cardiac Dysrhythmias

Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution24
Cold Blood Cardioplegia30

Cardiac Marker - Troponin-I

Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution5.7
Cold Blood Cardioplegia7.8

Cardiac Marker - Troponin-I

Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution3.0
Cold Blood Cardioplegia4.8

Cardiac Marker - Troponin-I

Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution.03
Cold Blood Cardioplegia.03

Cardiovascular Mortality

Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB)

Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution18.8
Cold Blood Cardioplegia22.2

Change in Troponin I

Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution9.65
Cold Blood Cardioplegia10.15

Changes in Left Ventricular (LV) Ejection Fraction (EF) by Transthoracic Echocardiogram (TTE)

LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery

Intervention% LV volume (Mean)
Cardioplegia: Custodiol HTK Solution-0.06
Cold Blood Cardioplegia1.9

Duration of Vasopressor / Inotropic Agent

Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionminutes (Median)
Cardioplegia: Custodiol HTK Solution340
Cold Blood Cardioplegia582

Intensive Care Unit (ICU) Length of Stay

Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission

Interventiondays (Median)
Cardioplegia: Custodiol HTK Solution3
Cold Blood Cardioplegia3

Myocardial Infarction

Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Postoperative Inotropic Infusion >20 Minutes

Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution47
Cold Blood Cardioplegia43

Time on Mechanically Assisted Ventilation

time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionhours (Median)
Cardioplegia: Custodiol HTK Solution10.5
Cold Blood Cardioplegia11.4

Trials

2 trials available for procaine and Injury, Myocardial Reperfusion

ArticleYear
Procaine and timing of aortic declamping affect ventricular reperfusion fibrillation.
    Annales chirurgiae et gynaecologiae, 1996, Volume: 85, Issue:1

    Topics: Adult; Aged; Cardioplegic Solutions; Coronary Artery Bypass; Coronary Disease; Double-Blind Method;

1996
[Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection].
    Kyobu geka. The Japanese journal of thoracic surgery, 1999, Volume: 52, Issue:10

    Topics: Aged; Blood; Cardioplegic Solutions; Cardiopulmonary Bypass; Female; Glucose; Heart Arrest, Induced;

1999

Other Studies

28 other studies available for procaine and Injury, Myocardial Reperfusion

ArticleYear
Astragalin and dihydromyricetin as adjuncts to histidine‑tryptophan‑ketoglutarate cardioplegia enhances protection during cardioplegic arrest.
    Molecular medicine reports, 2018, Volume: 18, Issue:3

    Topics: Animals; Apoptosis; Biomarkers; Cardioplegic Solutions; Cardiotonic Agents; Cytokines; Disease Model

2018
The efficiency of heart protection with HTK or HTK-N depending on the type of ischemia.
    Bioelectrochemistry (Amsterdam, Netherlands), 2019, Volume: 125

    Topics: Animals; Calcium; Cardioplegic Solutions; Female; Gap Junctions; Glucose; Guinea Pigs; Heart Arrest,

2019
Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368.
    BMC anesthesiology, 2019, 01-08, Volume: 19, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Gap Junc

2019
Design and Development of Novel 1,3,5-Triazine-Procaine Derivatives as Protective Agent against Myocardial Ischemia/Reperfusion Injury via Inhibitor of Nuclear Factor-κB.
    Pharmacology, 2019, Volume: 104, Issue:3-4

    Topics: Animals; Cardiotonic Agents; Catalase; Glutathione; Glutathione Peroxidase; Myocardial Reperfusion I

2019
Myocardial protection in donor heart preservation: a comparison between Bretschneider's histidine-tryptophan-ketoglutarate solution and cold blood cardioplegia.
    Transplantation proceedings, 2014, Volume: 46, Issue:4

    Topics: Adult; Cardioplegic Solutions; Chi-Square Distribution; Cold Temperature; Female; Glucose; Heart Arr

2014
Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution.
    Naunyn-Schmiedeberg's archives of pharmacology, 2014, Volume: 387, Issue:12

    Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhib

2014
Histidine-tryptophan-ketoglutarate solution with added ebselen augments myocardial protection in neonatal porcine hearts undergoing ischemia/reperfusion.
    Artificial organs, 2015, Volume: 39, Issue:2

    Topics: Animals; Antioxidants; Azoles; Glucose; Heart; Heart Arrest, Induced; Isoindoles; Mannitol; Myocardi

2015
Mechanoenergetic function and troponin T release following cardioplegic arrest induced by St Thomas' and histidine-tryptophan-ketoglutarate cardioplegia--an experimental comparative study in pigs.
    Interactive cardiovascular and thoracic surgery, 2009, Volume: 9, Issue:4

    Topics: Animals; Bicarbonates; Biomarkers; Calcium Chloride; Cardioplegic Solutions; Cardiopulmonary Bypass;

2009
Deferoxamine, the newly developed iron chelator LK-614 and N-alpha-acetyl-histidine in myocardial protection.
    Interactive cardiovascular and thoracic surgery, 2010, Volume: 10, Issue:2

    Topics: Animals; Cold Ischemia; Deferoxamine; Glucose; Heart Transplantation; Histidine; Hydroxamic Acids; I

2010
Superior myocardial preservation with HTK solution over Celsior in rat hearts with prolonged cold ischemia.
    Surgery, 2010, Volume: 148, Issue:2

    Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Cold Ischemia; Creatine K

2010
Polymerised placenta haemoglobin attenuates cold ischaemia/reperfusion injury in isolated rat heart.
    Microvascular research, 2011, Volume: 82, Issue:3

    Topics: Animals; Apoptosis; Cold Ischemia; Female; Glucose; Hemoglobins; Interleukin-1beta; Mannitol; Myocar

2011
Cardioprotective effects of low-dose cyclosporin A added to histidine-tryptophan-ketoglutarate cardioplegia solution prior to total myocardial ischemia: an in vitro rabbit heart study.
    Pharmacology, 2011, Volume: 88, Issue:3-4

    Topics: Adenosine Triphosphate; Animals; Cardioplegic Solutions; Cardiotonic Agents; Cyclosporine; Glucose;

2011
Cardioprotective effect of a hemoglobin-based oxygen carrier on cold ischemia/reperfusion injury.
    Cardiology, 2011, Volume: 120, Issue:2

    Topics: Animals; Blood Substitutes; Cold Ischemia; Down-Regulation; Glucose; Hemoglobins; Interleukin-6; Man

2011
Custodiol versus blood cardioplegia in complex cardiac operations: an Australian experience.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2013, Volume: 43, Issue:3

    Topics: Aged; Australia; Cardiac Surgical Procedures; Cardiotonic Agents; Chi-Square Distribution; Female; G

2013
Deleterious effect of hypothermia in myocardial protection against cold ischemia: a comparative study in isolated rat hearts.
    Transplantation proceedings, 2012, Volume: 44, Issue:8

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Cold Ischemia; Disaccharides; Edema

2012
New HTK-N46B cardioplegia provides superior protection during ischemia/reperfusion in failing hearts.
    The Journal of cardiovascular surgery, 2013, Volume: 54, Issue:3

    Topics: Animals; Biomarkers; Cardiac Surgical Procedures; Cardioplegic Solutions; Disease Models, Animal; Gl

2013
Initial reperfusion with magnesium after cardioplegic arrest attenuates myocardial reperfusion injury.
    The Thoracic and cardiovascular surgeon, 2002, Volume: 50, Issue:4

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Creatine Kinase; Glucose; Guinea Pi

2002
Cardioprotection by sevoflurane against reperfusion injury after cardioplegic arrest in the rat is independent of three types of cardioplegia.
    British journal of anaesthesia, 2002, Volume: 88, Issue:6

    Topics: Adenosine; Allopurinol; Anesthetics, Inhalation; Animals; Cardioplegic Solutions; Glucose; Glutathio

2002
Influence of superoxide dismutase on reperfusion injury in donor hearts preserved with Bretschneider-HTK cardioplegic solution.
    Cardiovascular surgery (London, England), 1993, Volume: 1, Issue:4

    Topics: Animals; Dogs; Glucose; Heart Transplantation; Inclusion Bodies; Mannitol; Mitochondria, Heart; Myoc

1993
Myocardial protection during prolonged ischaemic cardiac arrest: experimental evaluation of three crystalloid cardioplegic solutions.
    The Journal of cardiovascular surgery, 1994, Volume: 35, Issue:1

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Electrolytes; Evaluation Studies as

1994
Effect of HTK solution for myocardial preservation.
    The Journal of cardiovascular surgery, 1996, Volume: 37, Issue:3

    Topics: Animals; Cardiac Surgical Procedures; Cardioplegic Solutions; Glucose; Heart; Heart Arrest, Induced;

1996
Enflurane and isoflurane, but not halothane, protect against myocardial reperfusion injury after cardioplegic arrest with HTK solution in the isolated rat heart.
    Anesthesia and analgesia, 1998, Volume: 87, Issue:6

    Topics: Anesthetics, Inhalation; Animals; Cardioplegic Solutions; Creatine Kinase; Enflurane; Glucose; Halot

1998
Comparison of clinical outcome between histidine-triptophan-ketoglutalate solution and cold blood cardioplegic solution in mitral valve replacement.
    Journal of cardiac surgery, 1998, Volume: 13, Issue:1

    Topics: Blood; Cardioplegic Solutions; Case-Control Studies; Female; Glucose; Heart Valve Prosthesis Implant

1998
Beneficial effects of sevoflurane and desflurane against myocardial reperfusion injury after cardioplegic arrest.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1999, Volume: 46, Issue:11

    Topics: Anesthetics, Inhalation; Animals; Creatine Kinase; Desflurane; Diastole; Glucose; Heart Arrest, Indu

1999
Postischemic cardiac function recovery in the isolated rat heart: effects of adenosine deaminase and nucleoside transport inhibition.
    Langenbeck's archives of surgery, 2000, Volume: 385, Issue:8

    Topics: Adenine; Adenosine Deaminase; Affinity Labels; Animals; Cardioplegic Solutions; Disease Models, Anim

2000
Different preservation of myocardial capillary endothelial cells and cardiomyocytes during and after cardioplegic ischemia (25 degrees C) of canine hearts.
    Pathology, research and practice, 2002, Volume: 198, Issue:4

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endothelium, Vascular; Female

2002
Patterns of structural deterioration due to ischemia in Purkinje fibres and different layers of the working myocardium.
    The Thoracic and cardiovascular surgeon, 1991, Volume: 39, Issue:4

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endocardium; Glucose; Heart A

1991
[Ischemic-reperfusion injury of the heart: comparison of intra- and extracellular types of cardioplegic solutions].
    Ceskoslovenska fysiologie, 1989, Volume: 38, Issue:6

    Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Glucose; In Vitro Techniques; Magne

1989